Top Markets
Coin of the day
Cotinga Pharmaceuticals Inc. Cotinga Pharmaceuticals Inc.

Cotinga Pharmaceuticals Inc.

COTQF
Rang în acțiuni #42319
Cotinga Pharmaceuticals Inc. is a clinical-stage biopharmaceutical firm focused... Cotinga Pharmaceuticals Inc. is a clinical-stage biopharmaceutical firm focused on developing innovative treatments for cancer and other medical conditions currently lacking adequate solutions. Its leading therapeutic asset is COTI-2, an oral small molecule formulated to target the p53 tumor suppressor gene. The company is also progressing COTI-219, another oral small molecule compound, specifically engineered to inhibit mutant forms of KRAS without affecting the normal functions of the KRAS gene. In collaboration with St. Vincent's University Hospital, Cotinga is conducting research to evaluate COTI-2 when combined with eribulin for patients suffering from triple-negative metastatic breast cancer. The company, which was previously known as Critical Outcome Technologies Inc., rebranded to Cotinga Pharmaceuticals Inc. in January 2018. Its corporate base is situated in Toronto, Canada.
Preț acțiune
$0.0001
Ultima sincronizare: 2026-07-02
Capitalizare de piață
$2.20K
Schimbare (1 zi)
0.00%
Schimbare (1 an)
0.00%
Țară
CA
Tranzacționează Cotinga Pharmaceuticals Inc. (COTQF)

Categorie

Venituri pentru Cotinga Pharmaceuticals Inc. (COTQF)
Venituri în Aug 2026 TTM: 0
Conform celor mai recente rapoarte financiare ale Cotinga Pharmaceuticals Inc., venitul actual al companiei (TTM) este 0. În anul 2026, compania a avut un venit de 0 egal cu venitul din anul 2026, care a fost de 0. Venitul reprezintă suma totală generată de o companie din vânzarea de bunuri sau servicii. Spre deosebire de profit, cheltuielile nu sunt scăzute.
Istoricul veniturilor pentru Cotinga Pharmaceuticals Inc. din 2026 până în 2026
Venituri la sfârșitul fiecărui an
An Venituri Schimbă
Nu sunt suficiente date pentru perioada selectată.
Venituri pentru companii similare sau concurente
Companie Venituri Diferență de venituri Țara
$12.62B -
US
$6.02B -
NL
- -
CH
$10.11B -
BE
- -
KR